Abstract
Objective
This
study aimed to evaluate the clinical outcome of recurrent early-stage
high-risk epithelial ovarian cancer patients.
Methods
Demographic
and clinicopathological data were collected from women enrolled in GOG
157 who underwent surgical staging and had recurrent disease. Survival
probability was estimated using Kaplan-Meier method, and hazard ratio of
death was analyzed using Cox regression model.
Results
Of
74 women with recurrent early-stage high-risk ovarian cancer, the
median age at recurrence was 63 years; 93% were White, 2.7% were Black,
2.7% were Asian, and 1.4% were Others. Fifty-eight percent had stage I,
and the remainder had stage II disease. Clear cell, serous,
endometrioid, mucinous, and other tumors consisted of 28.4%, 25.7%,
24.3%, 16.2%, and 5.4% of patients, respectively; in addition, 36.5% had
ascites, 33.8% had positive cytology, and
43.2% had ruptured tumors.
Fifty-eight percent underwent three cycles, and 42% had six cycles of
adjuvant chemotherapy with paclitaxel and carboplatin. Recurrence was
diagnosed clinically in 46% and radiographically in 54% of women. The
median time from completion of primary chemotherapy to recurrence
(treatment-free interval, TFI) was
21 months. Overall, median survival
after recurrence was 24 months. Patients with longer (> 24 months)
TFI had a higher median survival after subsequent treatment at 35 months
compared to only 10 months in those who recurred ≤ 24 months (
p = 0.003).
Conclusions
Although patients with primary
early-stage high-risk ovarian cancer have an overall favorable
prognosis, survival after recurrence is poor and comparable to those
with recurrent advanced-stage disease. Novel therapeutic modalities are
warranted in these high-risk patients.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.